| Nome |
# |
|
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes, file e1f104fa-780d-8c6e-e053-1005fe0aa0dd
|
38
|
|
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells, file e1f104fb-b202-8c6e-e053-1005fe0aa0dd
|
11
|
|
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies, file e1f104fc-8f29-8c6e-e053-1005fe0aa0dd
|
8
|
|
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis, file e1f104fa-1d84-8c6e-e053-1005fe0aa0dd
|
7
|
|
Holter monitoring in AL amyloidosis: prognostic implications., file e1f104fa-29c9-8c6e-e053-1005fe0aa0dd
|
7
|
|
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis., file e1f104fa-80b6-8c6e-e053-1005fe0aa0dd
|
7
|
|
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis, file e1f104fd-1511-8c6e-e053-1005fe0aa0dd
|
7
|
|
A practical approach to the diagnosis of systemic amyloidoses, file e1f104fd-0717-8c6e-e053-1005fe0aa0dd
|
6
|
|
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL, file e1f104fa-2922-8c6e-e053-1005fe0aa0dd
|
5
|
|
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy, file e1f104fb-c961-8c6e-e053-1005fe0aa0dd
|
4
|
|
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses., file e1f104fa-8029-8c6e-e053-1005fe0aa0dd
|
3
|
|
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression, file e1f104fc-7a01-8c6e-e053-1005fe0aa0dd
|
3
|
|
New concepts in the treatment and diagnosis of amyloidosis, file e1f104fc-7a04-8c6e-e053-1005fe0aa0dd
|
3
|
|
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient, file e1f104fc-7b64-8c6e-e053-1005fe0aa0dd
|
3
|
|
Parkinsonism and dysautonomia: Multiple system atrophy?, file e1f104fc-7b66-8c6e-e053-1005fe0aa0dd
|
3
|
|
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients, file e1f104fc-7ec7-8c6e-e053-1005fe0aa0dd
|
3
|
|
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis, file e1f104fc-7fd9-8c6e-e053-1005fe0aa0dd
|
3
|
|
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis, file e1f104fc-8849-8c6e-e053-1005fe0aa0dd
|
3
|
|
Bortezomib in a Phase 1 Trial for Patients with Relapsed AL Amyloidosis: Cardiac Responses and Overall Effects, file e1f104fa-1cff-8c6e-e053-1005fe0aa0dd
|
2
|
|
Clotting alterations in primary systemic amyloidosis., file e1f104fa-1d88-8c6e-e053-1005fe0aa0dd
|
2
|
|
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients, file e1f104fa-7da7-8c6e-e053-1005fe0aa0dd
|
2
|
|
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients, file e1f104fb-54c6-8c6e-e053-1005fe0aa0dd
|
2
|
|
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options, file e1f104fc-7b62-8c6e-e053-1005fe0aa0dd
|
2
|
|
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients, file e1f104fc-7b68-8c6e-e053-1005fe0aa0dd
|
2
|
|
Predicting survival in light chain amyloidosis, file e1f104fc-7fdc-8c6e-e053-1005fe0aa0dd
|
2
|
|
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis, file 0fcd7bd1-84b2-424f-9bbd-727ab544caae
|
1
|
|
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies, file 57a27880-1fd4-4cc6-a91c-777064fa75b2
|
1
|
|
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis, file e1f104fa-05de-8c6e-e053-1005fe0aa0dd
|
1
|
|
Current treatment of AL amyloidosis, file e1f104fa-118b-8c6e-e053-1005fe0aa0dd
|
1
|
|
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum, file e1f104fa-18b7-8c6e-e053-1005fe0aa0dd
|
1
|
|
Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis, file e1f104fa-1909-8c6e-e053-1005fe0aa0dd
|
1
|
|
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44, file e1f104fa-190b-8c6e-e053-1005fe0aa0dd
|
1
|
|
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study, file e1f104fa-190c-8c6e-e053-1005fe0aa0dd
|
1
|
|
The proteasome load vs. capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition, file e1f104fa-1b63-8c6e-e053-1005fe0aa0dd
|
1
|
|
End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link?, file e1f104fa-1b66-8c6e-e053-1005fe0aa0dd
|
1
|
|
Bortezomib in the treatment of AL amyloidosis: targeted therapy?, file e1f104fa-1bad-8c6e-e053-1005fe0aa0dd
|
1
|
|
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis, file e1f104fa-1bdc-8c6e-e053-1005fe0aa0dd
|
1
|
|
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis, file e1f104fa-1cfe-8c6e-e053-1005fe0aa0dd
|
1
|
|
Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis, file e1f104fa-2829-8c6e-e053-1005fe0aa0dd
|
1
|
|
Transplantation vs. conventional-dose therapy for amyloidosis, file e1f104fa-28af-8c6e-e053-1005fe0aa0dd
|
1
|
|
Valore prognostico della presenza di disturbi della conduzione
cardiaca nei pazienti affetti da amiloidosi AL, file e1f104fa-2ae4-8c6e-e053-1005fe0aa0dd
|
1
|
|
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach, file e1f104fa-7724-8c6e-e053-1005fe0aa0dd
|
1
|
|
Update on treatment of light chain amyloidosis, file e1f104fa-772b-8c6e-e053-1005fe0aa0dd
|
1
|
|
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis, file e1f104fa-7d92-8c6e-e053-1005fe0aa0dd
|
1
|
|
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans, file e1f104fa-7d98-8c6e-e053-1005fe0aa0dd
|
1
|
|
Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis, file e1f104fa-803a-8c6e-e053-1005fe0aa0dd
|
1
|
|
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli, file e1f104fa-803f-8c6e-e053-1005fe0aa0dd
|
1
|
|
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis, file e1f104fa-80a7-8c6e-e053-1005fe0aa0dd
|
1
|
|
The challenge of systemic immunoglobulin light-chain amyloidosis (Al), file e1f104fa-833d-8c6e-e053-1005fe0aa0dd
|
1
|
|
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis, file e1f104fb-598a-8c6e-e053-1005fe0aa0dd
|
1
|
|
Bone marrow amyloidosis., file e1f104fb-5b3a-8c6e-e053-1005fe0aa0dd
|
1
|
|
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome, file e1f104fb-cdc7-8c6e-e053-1005fe0aa0dd
|
1
|
|
The elusive pathogenesis of schnitzler syndrome, file e1f104fc-6981-8c6e-e053-1005fe0aa0dd
|
1
|
|
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts, file e1f104fc-7425-8c6e-e053-1005fe0aa0dd
|
1
|
|
The lung in amyloidosis, file e1f104fc-7427-8c6e-e053-1005fe0aa0dd
|
1
|
|
Novel Therapies in Light Chain Amyloidosis, file e1f104fc-7429-8c6e-e053-1005fe0aa0dd
|
1
|
|
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity, file e1f104fc-7494-8c6e-e053-1005fe0aa0dd
|
1
|
|
Light chain amyloidosis, file e1f104fc-7498-8c6e-e053-1005fe0aa0dd
|
1
|
|
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis, file e1f104fc-7b61-8c6e-e053-1005fe0aa0dd
|
1
|
|
Treatment of AL amyloidosis with bendamustine: A study of 122 patients, file e1f104fc-7fd2-8c6e-e053-1005fe0aa0dd
|
1
|
|
Systemic immunoglobulin light chain amyloidosis, file e1f104fc-7fd4-8c6e-e053-1005fe0aa0dd
|
1
|
|
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations, file e1f104fc-7fd7-8c6e-e053-1005fe0aa0dd
|
1
|
|
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis, file e1f104fc-7fde-8c6e-e053-1005fe0aa0dd
|
1
|
|
null, file e1f104fc-89ae-8c6e-e053-1005fe0aa0dd
|
1
|
|
null, file e1f104fc-89af-8c6e-e053-1005fe0aa0dd
|
1
|
|
Validation of a new prognostic body composition parameter in cancer patients, file e1f104fc-ddad-8c6e-e053-1005fe0aa0dd
|
1
|
|
European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis, file e1f104fc-fe34-8c6e-e053-1005fe0aa0dd
|
1
|
|
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, file e1f104fd-0271-8c6e-e053-1005fe0aa0dd
|
1
|
|
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis, file e1f104fd-0761-8c6e-e053-1005fe0aa0dd
|
1
|
|
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis, file e1f104fd-0b9b-8c6e-e053-1005fe0aa0dd
|
1
|
|
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis, file e1f104fd-1eed-8c6e-e053-1005fe0aa0dd
|
1
|
|
Search for AL amyloidosis risk factors using Mendelian randomization, file e1f104fd-2283-8c6e-e053-1005fe0aa0dd
|
1
|
| Totale |
185 |